23. The fusion polypeptide of claim 21, wherein the α1,3 galactosyltransferase is porcine.

26. The fusion polypeptide of claim 21, wherein said second polypeptide comprises an Fc region of an immunoglobulin heavy chain.

28. The fusion protein of claim 21, wherein the first polypeptide comprises more Galα1, 3Gal epitopes than a wild-type P-selectin glycoprotein ligand-1 polypeptide.

29. (new) A dimerized fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide:

(a) comprises the extracellular portion of a P-selectin glycoprotein ligand-1; and

(b) is glycosylated by an α1,3 galactosyltransferase and

the second polypeptide comprises immunoglobulin heavy chain polypeptide.

30. (new) The fusion polypeptide of claim 29, wherein the first polypeptide comprises multiple Galα1, 3Gal epitopes.

31. (new) The fusion polypeptide of claim 29, wherein the α1,3 galactosyltransferase is porcine.

32. (new) The fusion polypeptide of claim 29, wherein said second polypeptide comprises an Fc region of an immunoglobulin heavy chain.

33. (new) The fusion protein of claim 29, wherein the first polypeptide comprises more Galα1, 3Gal epitopes than a wild-type P-selectin glycoprotein ligand-1 polypeptide.

34. (new) A dimerized fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide:

(a) comprises a part of a P-selectin glycoprotein ligand-1 that mediates binding to selectin; and

(b) is glycosylated by an α1,3 galactosyltransferase and

the second polypeptide comprises an immunoglobulin polypeptide.

35. (new) The fusion polypeptide of claim 34, wherein the first polypeptide comprises multiple Galα1, 3Gal epitopes.

36. (new) The fusion polypeptide of claim 34, wherein the α1,3 galactosyltransferase is porcine.

37. (new) The fusion polypeptide of claim 34, wherein said second polypeptide comprises an Fc region of an immunoglobulin heavy chain.

38. (new) The fusion protein of claim 34, wherein the first polypeptide comprises more Galα1, 3Gal epitopes than a wild-type P-selectin glycoprotein ligand-1 polypeptide.

REMARKS

Upon entry of the foregoing amendments, claims 21-23, 26, and 28 are under consideration. Support for the amendment to claim 21, is found in the specification at page 5, lines 7-9 and lines 37-38. Support for new independent claim 29 is found at

Support for new independent claim 34 is found at

§ 112, First Paragraph Rejection: Written Description

The Examiner has rejected claims 21- 26, and 28 under 35 USC § 112 first paragraph for lack of written description. The Examiner asserts that the specification and the claims as originally filed does not provide support for the invention as now claimed.

The Examiner alleges that there is lack of written description for the term "at least a region of a P-selectin glycoprotein ligand-1... at least a region of an immunoglobulin polypeptide," in Claim 21. Claim 21, from which claims 22-26 and 28 depend, has been amended to delete the phrase "at least a region of" a P-selectin glycoprotein ligand-1 and a heavy